Journal of Hepatology and Gastrointestinal disorders
Open Access
ISSN: 2475-3181
+44-20-4587-4809
ISSN: 2475-3181
+44-20-4587-4809
Dr. Joise
Believers Church Medical College Hospital, Kerala, India
Scientific Tracks Abstracts: jhgd
The landscape of therapeutic options in Advanced Metastatic Cancer have changed dramatically during recent years. The introduction of targeted therapies has had a major impact on therapeutic efficacy. Sorafenib is a vascular endothelial growth factor (VEGF) signaling pathway inhibitor, which suppresses tumour growth and invasion. Sorafenib is commonly used as an adjunct therapy to the standard chemotherapy in advanced Hepatocellular carcinoma. Anecdotal evidence exists on the laryngeal side- effects in those patients exposed to other VEGFR antagonists. In this case we report, we present a case of Sorafenib induced dysphonia in a 61 year old male patient with Advanced HCC. To our knowledge this is the first case of dysphonia associated with Sorafenib. We have presented the short vignette for 2 primary reasons. 1. VEGF inhibitor induced vocal cord changes more often under diagnosed and under reported side effect and 2. because the patient can be a bellwether for development of formerly rare side effects like dysphonia if continued on the same drug.
Dr. Joise has completed Pharm D in 2020 from Kerala University of Health Sciences, India She is working as a Clinical Pharmacist in Believers Church Medical College Hospital, Thiruvalla, India. She has more than 7 papers in reputed journals and her primary areas of interest lies in Clinical Research and Medical writing.